Docoh
Loading...

ADVM Adverum Biotechnologies

Adverum Biotechnologies, publicly traded is a clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, designed as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. On May 12, 2016, Adverum formed as a company after the closing on a transaction with Annapurna Therapeutics. The company announced its common stock will begin trading on Nasdaq under the symbol ADVM as of the open of market.

Company profile

Ticker
ADVM
Exchange
Website
CEO
Leone Patterson
Employees
Incorporated
Location
Fiscal year end
Former names
Avalanche Biotechnologies, Inc.
SEC CIK

ADVM stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

6 May 21
17 May 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 49.2M 49.2M 49.2M 49.2M 49.2M 49.2M
Cash burn (monthly) 4.74M 6.83M 9.55M 10.23M 7.44M 7.33M
Cash used (since last report) 7.43M 10.71M 14.97M 16.05M 11.66M 11.5M
Cash remaining 41.77M 38.49M 34.23M 33.16M 37.54M 37.71M
Runway (months of cash) 8.8 5.6 3.6 3.2 5.0 5.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 May 21 Patrick Machado Stock Option Common Stock Grant Aquire A No No 3.7 12,500 46.25K 12,500
12 May 21 Patrick Machado Stock Option Common Stock Grant Aquire A No No 3.7 40,000 148K 40,000
12 May 21 Gasmi Mehdi Stock Option Common Stock Grant Aquire A No No 3.7 40,000 148K 40,000
12 May 21 Scopa James Paul Stock Option Common Stock Grant Aquire A No No 3.7 40,000 148K 40,000
12 May 21 Lupher, Jr. Mark L. Stock Option Common Stock Grant Aquire A No No 3.7 40,000 148K 40,000
12 May 21 Svoronos Dawn Stock Option Common Stock Grant Aquire A No No 3.7 40,000 148K 40,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Risks
  • We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.
  • We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs for at least twelve months from the date of this filing. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.
  • We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.
  • Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.
  • Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.
  • The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, either in preclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.
  • The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.
  • Our gene therapy platform is based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.
  • Preliminary and interim data from our clinical trials that we may announce or publish from time to time may change as each clinical trial progresses.
  • Fast Track designation for ADVM‑022 may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that ADVM‑022 will receive marketing approval in the United States.
  • We may not be successful in our efforts to identify or discover additional product candidates.
  • If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.
  • If we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.
  • We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.
  • We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.
  • We have relied, and expect to continue to rely, on third parties to conduct some or all aspects of our vector production, process development, assay development, product manufacturing, product testing, protocol development, and research, and these third parties may not perform satisfactorily.
  • We will rely on third parties to conduct some preclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.
  • Our reliance on third parties requires us to share our trade secrets and other confidential information, which increases the possibility that a competitor will discover them or that our confidential information, including trade secrets, will be misappropriated or disclosed.
  • Our success depends on our ability to protect our intellectual property and our proprietary technologies.
  • Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.
  • We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
  • Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.
  • The patent protection and patent prosecution for some of our product candidates are dependent on third parties.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.
  • We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged administratively or in court.
  • Some intellectual property that we have in-licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.
  • We may fail to comply with any of our obligations under existing agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.
  • Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.
  • If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.
  • Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.
  • Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
  • If the market for our product candidate, if approved, in the treatment of wet AMD or DME or any other indication we seek to treat is smaller than we believe it is, or if our product candidate is approved with limitations that reduce the market size, our future revenue may be adversely affected, and our business may suffer.
  • If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates, if approved, may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.
  • Due to the novel nature of our technology and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates.
  • We may not be successful in establishing and maintaining development or other strategic collaborations, which could adversely affect our ability to develop and commercialize product candidates and receive milestone and/or royalty payments.
  • Governments may impose price controls, which may adversely affect our future profitability.
  • We may form strategic alliances in the future, and we may not realize the benefits of such alliances.
  • We have no sales, marketing or distribution capabilities, and we would have to invest significant resources to develop these capabilities.
  • Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.
  • We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.
  • We may encounter difficulties in managing our growth and expanding our operations successfully.
  • If our security measures are compromised now, or in the future, or the security, confidentiality, integrity or availability of our information technology, software, services, communications or data is compromised, limited or fails, this could result in a materially adverse effect, including harm to our reputation, significant fines, penalties and liability, breach notification obligations, loss of customers or sales, and a material disruption of our product development programs.
  • If we fail to comply with applicable state and federal healthcare laws and regulations, we may be subject to civil or criminal penalties and/or exclusion from federal and/or state healthcare programs.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
  • We are subject to evolving and increasingly stringent laws, regulations, contractual obligations, and other legal obligations related to privacy, data protection, and data security, and our actual or perceived failure to comply with them could harm our business, subject us to litigation, fines, penalties or adverse publicity and reputational damage, interrupt our clinical trials, or otherwise adversely affect the value of our business.
  • We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, “Trade Laws”). We can face serious consequences for violations.
  • We and our development partners, third-party manufacturer and suppliers use biological materials and use or may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.
  • We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.
  • Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with our code of conduct or regulatory standards and requirements.
  • Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business and financial condition.
  • Our ability to use net operating loss carryforwards and other tax attributes may be limited by the Code.
  • The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.
  • If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to our at-the-market sales agreement, licensing or collaboration arrangements, or acquisitions, stockholders may experience immediate dilution and, as a result, our stock price may decline.
  • Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
  • We have been subject to securities class action lawsuits in the past, and could be subject to additional such lawsuits in the future, which could result in substantial losses and may divert management’s time and attention from our business.
  • Our quarterly operating results may fluctuate significantly.
  • Our certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
Management Discussion
  • The $7.5 million license revenue for the three months ended March 31, 2021 was related to an upfront payment received in January 2021 upon execution of a license agreement entered with Lexeo Therapeutics, Inc (“Lexeo”).
  • Research and development expense increased $5.2 million to $20.0 million for the three months ended March 31, 2021 from $14.8 million for the three months ended March 31, 2020. This overall increase was primarily related to a $3.5 million increase in personnel-associated costs including higher salaries, stock-based compensation expense, and bonuses mainly driven by headcount increase, and increases in severance and employee paid-time-off expense. The overall increase was also caused by a $0.8 million increase in production costs related to our ADVM-022 product candidates and earlier-stage research programs and a $0.7 million increase in clinical trial-related expenses. Stock-based compensation included in research and development expenses was $2.3 million for the first quarter of 2021, compared to $1.2 million for the first quarter of 2020.
  • For the periods presented, our research and development activities were attributable to our wet AMD, DME, rare disease programs and earlier-stage research programs. We expect that research and development expenses will increase in future periods as we continue to invest in advancing our gene therapy product candidate ADVM-022 and earlier-stage research programs.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: adapt, adequacy, agent, aim, alerting, Alexander, analyzed, anesthesiologist, Annex, approach, arbitrage, ASC, asset, ataxia, average, Banque, batch, Biden, bill, black, body, bound, box, BPI, Brazil, Britain, broader, cardiomyopathy, Carolina, chairman, Commerce, Commissioner, comprehensive, constantly, contest, conventional, Cooperation, coterminously, Cowen, CPRA, credential, currency, cybersecurity, de, Deal, death, decentralized, dedicated, departure, destruction, diverge, DMC, domestic, Durham, earliest, EC, EEA, eighteen, embodied, embodying, England, entirety, entitlement, estate, expert, faster, FDPIC, feasible, framework, Friedreich, FTC, gathered, genomic, Geral, GMP, Great, headquartered, hijacking, iii, imaging, immunologic, inclusion, indemnity, infect, inseverability, inseverable, Ireland, irrevocable, iv, Justice, kind, landlord, Lei, letter, leukemia, Lexeo, LGPD, licensure, lifespan, LLC, loan, lodge, LUXTURNA, MA, MAA, malware, mandatory, meantime, mechanism, medicinal, misuse, modestly, NC, necessity, North, Northern, notification, official, ophthalmic, optimize, overturning, owner, parallel, parking, password, perspective, pharmacoeconomic, phishing, Political, prepaid, prospective, proxy, Publique, purpose, qualitative, quantitative, ransomware, reaction, real, reconsider, redirect, regime, reliable, remote, rentable, rescind, residency, retested, revise, revised, reward, rolling, runway, Scotland, session, Shield, simplify, Simplifying, software, solution, sponsor, staffing, stuffing, supervisory, Supplementary, SUSAR, Suspected, Switzerland, tenant, territory, theft, thereof, thereunder, TW, twelve, unchanged, undergoing, undermine, undiscounted, unilaterally, unmasked, upfront, vaccine, variable, Virginia, vivo, waived, workforce, ZOLGENSMA
Removed: accuracy, adjustment, affirmed, Aid, Anne, Arm, assessed, attest, ballot, beneficiary, billion, biosimilar, Bipartisan, Blueprint, Cadillac, calling, cap, certiorari, cGMP, choroidal, Circuit, circumvent, clinically, close, cohort, computer, Concurrently, confidence, consequentially, corridor, creating, deposit, device, devoted, disaster, discount, discrimination, dividend, donut, electrical, evolution, feedback, firm, gap, GenSight, hole, importation, incentivize, insurer, judge, Kenner, Likewise, list, loosen, malfeasance, mandated, manmade, mg, moved, Nasdaq, negotiating, neovascular, neovascularization, NHP, package, passing, percent, permitting, personally, pharmacy, pigmentosa, pocket, predominantly, presentation, proper, proposal, recombinant, regimen, reimbursable, relationship, remanded, remediate, retention, reversed, Scopa, solicited, Switching, telecommunication, terrorism, tolerated, Trump, Trust, war, water

Patents

APP
Utility
Modified Aav Capsids and Uses Thereof
6 May 21
The present disclosure provides modified adeno-associated virus (AAV) virions with altered capsid proteins, where the modified AAV virions exhibit greater infectivity of retinal cells when administered to the eye or greater infectivity of liver cells when administered intravenously.
APP
Utility
Methods of Treating Ocular Neovascular Diseases Using AAV2 Variants Encoding Aflibercept
8 Apr 21
Provided are methods for treating an ocular neovascular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and flanked by AAV2 inverted terminal repeats (ITRs), and b) an AAV2 capsid protein comprising an amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to an AAV2 VP1 capsid protein.
APP
Utility
Compositions and Methods for Enhanced Gene Expression
11 Feb 21
The present disclosure provides polynucleotide cassettes, expression vectors, and methods for the expression of a gene in mammalian cells.
APP
Utility
Variant Aav Capsids for Intravitreal Delivery
28 Oct 20
Provided are variant adeno-associated virus (AAV) capsid proteins and recombinant AAV virions having one or more variant AAV capsid proteins.
APP
Utility
Sequential Intravitreal Administration of Aav Gene Therapy to Contralateral Eyes
23 Sep 20
Provided are methods of treating an ocular disease or disorder in a subject, comprising: administering a unit dose of a pharmaceutical composition to a first eye the subject via intravitreal (IVT) injection at a first time point, and administering a second unit dose of the pharmaceutical composition to a contralateral eye of the subject via IVT injection at a second time point.